Enhancing Chordoma Radiotherapy: Ta@PVP Nanoparticles as Potent Radiosensitizers
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.4c19601 ↗At a glance
Journal article in ACS Applied Materials & Interfaces, 2025. Written by Wancheng Li and 11 co-authors. Institution: CAS Key Laboratory for the Biological Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing…. Major MEDLINE topics: Radiation-Sensitizing Agents, Chordoma, Tantalum, Nanoparticles. Cited 6 times so far (Crossref); 50 references. Funded by: National Key Research and Development Program of China, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (original language)
Surgical resection and high-dose radiotherapy constitute the standard therapeutic approaches for chordoma. However, the efficacy of radiotherapy is often compromised by the tumor microenvironment's hypoxic conditions, which confer radiation resistance, and by the potential damage to adjacent spinal cord and neural structures from elevated radiation doses. To address these challenges, we employed high biocompatible poly(vinylpyrrolidone)-modified tantalum nanoparticles (Ta@PVP NPs) as a potent radiosensitizer to augment the radiotherapy sensitivity of chordoma. Upon exposure to X-ray irradiation, Ta@PVP NPs demonstrated the capability to efficiently deposit X-ray radiation energy within the tumor microenvironment, subsequently generating reactive oxygen species (ROS) that induce oxidative stress in the tumor. Both in vitro and in vivo experiments revealed that Ta@PVP NPs significantly enhanced the cytotoxic effects of X-ray, thereby markedly inhibiting the proliferation of chordoma cells and impeding tumor growth. This study explored the radiosensitization potential of Ta@PVP NPs in the context of chordoma, highlighting the application of radiosensitizers as a promising strategy to augment the efficacy of chordoma radiotherapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- CAS Key Laboratory for the Biological Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China.
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
- Department of Neurosurgery, Anshan Central Hospital of China Medical University, Anshan 114000, China.
- College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
- Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China.
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universi…
ORCID profiles: Zhanjun Gu, Fuping Gao
Funding
- National Key Research and Development Program of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- The directional institutionalized scientific research platform relies on Beijing Synchrotron Radiation Facility of Chinese Academy of Sciences
Cite
APA
Li, W., Zhang, S., Liu, L., Li, M., He, J., Meng, Q., Kang, J., Zhou, D., Gao, L., Bai, J., Gu, Z., & Gao, F. (2025). Enhancing Chordoma Radiotherapy: Ta@PVP Nanoparticles as Potent Radiosensitizers. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c19601
Vancouver
Li W, Zhang S, Liu L, Li M, He J, Meng Q, et al. Enhancing Chordoma Radiotherapy: Ta@PVP Nanoparticles as Potent Radiosensitizers. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.4c19601
BibTeX
@article{Li2025,
author = {Li, Wancheng and Zhang, Shuheng and Liu, Linhong and Li, Mingxuan and He, Jinfeng and Meng, Qingguo and Kang, Jiali and Zhou, Dabiao and Gao, Liang and Bai, Jiwei and Gu, Zhanjun and Gao, Fuping},
title = {Enhancing Chordoma Radiotherapy: Ta@PVP Nanoparticles as Potent Radiosensitizers},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.4c19601}
}
EUVIMED